DCAF15 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL27374912	0.83	7/20
SCHEMBL1043883	0.37	3/20
SCHEMBL5844634	0.44	2/20
SCHEMBL3245760	0.44	2/20
SCHEMBL28900069	0.42	2/20
SCHEMBL5845512	0.40	2/20
SCHEMBL20023786	0.39	2/20
SCHEMBL31494466	0.39	2/20
SCHEMBL5845663	0.38	2/20
SCHEMBL20023788	0.38	2/20
SCHEMBL31494477	0.38	2/20
SCHEMBL5845392	0.37	2/20
SCHEMBL27981781	0.36	2/20
SCHEMBL9693687	0.54	1/20
SCHEMBL10839105	0.48	1/20
SCHEMBL30125140	0.48	1/20
SCHEMBL13413754	0.47	1/20
SCHEMBL1383245	0.46	1/20
SCHEMBL11244506	0.46	1/20
SCHEMBL2817446	0.45	1/20

Clinical trials — most relevant to DCAF15 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients	PHASE4	NOT_YET_RECRUITING
A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy	PHASE1/PHASE2	RECRUITING
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
Phase II Prospective Cohort Study of Intravesical Recombinant Human Type 5 Adenovirus Injection for Treatment of High-Risk Non-Muscle Invasive Bladder Cancer: Evaluating Efficacy and Safety	PHASE2	NOT_YET_RECRUITING
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer	PHASE2	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study	nan	RECRUITING
Whole-genome Sequencing Study in Patients With Diminished Ovarian Reserve	nan	UNKNOWN
Serum DCAMKL1 Pre and Post Treatment in Patients With Pancreatic Cancer	nan	ACTIVE_NOT_RECRUITING
Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants	nan	RECRUITING
Epileptic Syndromes in Infants and Early Childhood	nan	UNKNOWN
Tecfidera Diffusion Tensor Imaging	nan	COMPLETED
Implication of Long Non-coding RNA CCDC144NL-AS1/Micro RNA-143-3p Axis Expression Level as Novel Signature in Colorectal Cancer	nan	COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Assessment Of Long Noncoding RNA CCAT1 In Colorectal Cancer Patients	nan	UNKNOWN
Better Delineation of DDX3X Related Phenotype and Epigenetic Signature.	nan	UNKNOWN
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders	nan	RECRUITING
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients	nan	RECRUITING
Genetic and Physical Characteristics of Rett Syndrome	nan	COMPLETED
Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC)	nan	UNKNOWN
Functional Pharmacogenomics of Childhood Acute Lymphoblastic Leukemia in Taiwan	nan	UNKNOWN
Corpus Callosum Agenesis and Intellectual Disability	nan	COMPLETED
Characterization of Microbiological and Genetic Features in Prostate Cancer and Their Association with Disease Stage	nan	ENROLLING_BY_INVITATION
Genetic Variation in TRAF3IP2 (rs13190932)	nan	RECRUITING
New Signaling Pathway Targeting Systemic Lupus Erythematosus	nan	UNKNOWN
Quantitative Assessment of the Etiologies of Megalencephaly Associated With a Detectable Tumor Risk	nan	NOT_YET_RECRUITING
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA	nan	RECRUITING
Muscle Tissue Bank for Muscular Dystrophy	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a DCAF15 binder may also engage these)

Protein	Name	Similarity
Q3SZD5	—	1.000	Q3SZD5 →
A2BDA5	—	1.000	A2BDA5 →
Q6PFH3	—	1.000	Q6PFH3 →
Q9QXM1	—	0.982	Q9QXM1 →
Q62925	—	0.981	Q62925 →
Q5XPI4	—	0.981	Q5XPI4 →
Q9EP53	—	0.981	Q9EP53 →
Q7L4E1	—	0.980	Q7L4E1 →
Q8BK03	—	0.980	Q8BK03 →
PIK3C2B	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	0.980	landscape →
Q8CEC0	—	0.980	Q8CEC0 →
A7UA95	—	0.980	A7UA95 →
O15259	—	0.980	O15259 →
AXIN2	Axin-2	0.980	landscape →
O35253	—	0.979	O35253 →
O88406	—	0.979	O88406 →
Q8JZL1	—	0.979	Q8JZL1 →
Q8K245	—	0.979	Q8K245 →
Q9ULM0	—	0.979	Q9ULM0 →
Q9Z136	—	0.979	Q9Z136 →
Q5F479	—	0.979	Q5F479 →
P53349	—	0.979	P53349 →
Q8N9B5	—	0.979	Q8N9B5 →
Q62141	—	0.979	Q62141 →
KAT2B	Histone acetyltransferase KAT2B	0.979	landscape →
Q9H6J7	—	0.979	Q9H6J7 →
Q92574	—	0.978	Q92574 →
O88566	—	0.978	O88566 →
O88480	—	0.978	O88480 →
Q7TP65	—	0.978	Q7TP65 →